BACKGROUND/AIM: In patients with non-malignant diseases, mixed chimerism is not a rare phenomenon. The clinical impacts of chimerism following allogeneic haematopoietic stem cell transplantation (allo-HSCT) in children with congenital anaemia (CA) and severe aplastic anaemia (SAA) were analysed. PATIENTS AND METHODS: We studied twenty-seven consecutive children with congenital and acquired anaemia who had undergone allogeneic haematopoietic stem cell transplantations. In the observed group of patients, the median of the follow-up was 6.12 years (2.00-14.8 years). RESULTS: Overall survival (OS) did not depend on the type of disease p=0.1. OS did not significantly differ in patients who received more than 5x106/kg stem cells (91%) and those who received less than 5x106/kg (85%) (p=0.61). Two patterns of stable mixed chimerism (SMC) were observed: SMC (95-97% cells of the donor), and SMC with a fluctuation between 50-90% of the cells of the donor. None of the surviving patients received immunosuppression treatments of chronic Graft-versus-Host Disease (cGvHD). CONCLUSION: Our results showed that mixed chimerism did not influence the survival of children with congenital and aplastic anaemia following allo-HSCT. Copyright
BACKGROUND/AIM: In patients with non-malignant diseases, mixed chimerism is not a rare phenomenon. The clinical impacts of chimerism following allogeneic haematopoietic stem cell transplantation (allo-HSCT) in children with congenital anaemia (CA) and severe aplastic anaemia (SAA) were analysed. PATIENTS AND METHODS: We studied twenty-seven consecutive children with congenital and acquired anaemia who had undergone allogeneic haematopoietic stem cell transplantations. In the observed group of patients, the median of the follow-up was 6.12 years (2.00-14.8 years). RESULTS: Overall survival (OS) did not depend on the type of disease p=0.1. OS did not significantly differ in patients who received more than 5x106/kg stem cells (91%) and those who received less than 5x106/kg (85%) (p=0.61). Two patterns of stable mixed chimerism (SMC) were observed: SMC (95-97% cells of the donor), and SMC with a fluctuation between 50-90% of the cells of the donor. None of the surviving patients received immunosuppression treatments of chronic Graft-versus-Host Disease (cGvHD). CONCLUSION: Our results showed that mixed chimerism did not influence the survival of children with congenital and aplastic anaemia following allo-HSCT. Copyright
Authors: Hilary L Haines; Jack J Bleesing; Stella M Davies; Lindsey Hornung; Michael B Jordan; Rebecca A Marsh; Alexandra H Filipovich Journal: Biol Blood Marrow Transplant Date: 2014-10-18 Impact factor: 5.742
Authors: J Dubovsky; H Daxberger; G Fritsch; D Printz; C Peters; S Matthes; H Gadner; T Lion; N Muller-Bérat Journal: Leukemia Date: 1999-12 Impact factor: 11.528
Authors: Carmem Bonfim; Lisandro Ribeiro; Samantha Nichele; Marco Bitencourt; Gisele Loth; Adriana Koliski; Vaneuza A M Funke; Daniela V Pilonetto; Noemi F Pereira; Mary E D Flowers; Eunike Velleuer; Ralf Dietrich; Anders Fasth; Cassius C Torres-Pereira; Paola Pedruzzi; Mary Eapen; Ricardo Pasquini Journal: Biol Blood Marrow Transplant Date: 2016-03-11 Impact factor: 5.742
Authors: Arwen Stikvoort; Mikael Sundin; Mehmet Uzunel; Jens Gertow; Berit Sundberg; Marie Schaffer; Jonas Mattsson; Michael Uhlin Journal: PLoS One Date: 2016-05-06 Impact factor: 3.240
Authors: Jan Styczynski; Robert Debski; Krzysztof Czyzewski; Katarzyna Gagola; Ewa Marquardt; Krzysztof Roszkowski; Janusz Winiecki; Ninela Irga-Jaworska; Marcin Hennig; Katarzyna Muszynska-Roslan; Marcin Plonowski; Tomasz Ociepa; Monika Lecka; Joanna Konieczek; Przemyslaw Galazka; Monika Pogorzala; Monika Richert-Przygonska; Mariusz Wysocki Journal: In Vivo Date: 2021 Nov-Dec Impact factor: 2.155